Linked e-resources
Details
Table of Contents
2.3 The Auxiliary [beta]1a Subunit
2.4 The Adaptor Protein STAC3
3 Skeletal Muscle Channelopathies
3.1 CaV1.1 Channelopathies
3.1.1 Hypokalemic Periodic Paralysis (HypoPP)
3.1.2 Normokalemic Periodic Paralysis (NormoPP)
3.1.3 CaV1.1 Related Myopathies
3.2 RyR1 Channelopathies
3.2.1 Central Core Disease (CCD) and Dusty Core Disease (DuCD)
3.2.2 Other Congenital Myopathies Caused by RyR1 Mutations
3.3 STAC3 Channelopathies
3.3.1 Native American Myopathy (NAM)
3.4 Channelopathies Caused by Several EC Coupling Proteins
3.4.1 Malignant Hyperthermia (MH) Susceptibility
Intro
Preface
1. A Bumpy Road Toward Drug Therapies in Ca2+ Channelopathies
2. Toward Advanced Technology Medicinal Products Targeting Ca2+-Channels
3. Ca2+-Channel Modulation: New Discoveries Answer (Very) Old Questions
Contents
Part I: Modulation
CaV1.1 Calcium Channel Signaling Complexes in Excitation-Contraction Coupling: Insights from Channelopathies
1 Skeletal Muscle Excitation-Contraction (EC) Coupling
2 Essential Proteins for Skeletal Muscle Excitation-Contraction Coupling
2.1 The Voltage-Sensor CaV1.1
2.2 The Calcium Release Channel RyR1
3.4.2 Myotonic Dystrophy Type 1 (DM1)
4 Summary and Perspective
References
Mechanisms of Vascular CaV1.2 Channel Regulation During Diabetic Hyperglycemia
1 Introduction
2 Role of CaV1.2 in Smooth Muscle Cells
3 Effects of Diabetic Hyperglycemia on Vascular CaV1.2
4 Mechanisms
5 Pathophysiological Impact
6 Conclusions/Future Directions
References
Sympathetic Nervous System Regulation of Cardiac Calcium Channels
1 Introduction
2 Biophysical Signature of Adrenergic Regulation of L-Type Channels
3 Molecular Mechanisms Underlying L-Type Upregulation
1 Cardiovascular CaV1.2 Channel at a Glance
2 Galectin-1
2.1 Galectin-1 Overview
2.2 Galectin-1-Mediated CaV1.2 Regulation in Hypertension
2.3 Galectin-1 in Cardiac Diseases
2.4 Regulatory Signalling of Galectin-1
2.5 Other Galectins
2.5.1 Galectin Localization and Functions
2.5.2 Galectin-3 in Cardiovascular Diseases
3 Cereblon
4 CaV1.2, Sialylation, and COVID-19
5 Concluding Remarks
References
Part II: Pharmacological Approaches
The Role of Striatal Cav1.3 Calcium Channels in Therapeutics for Parkinsonś Disease
2.4 The Adaptor Protein STAC3
3 Skeletal Muscle Channelopathies
3.1 CaV1.1 Channelopathies
3.1.1 Hypokalemic Periodic Paralysis (HypoPP)
3.1.2 Normokalemic Periodic Paralysis (NormoPP)
3.1.3 CaV1.1 Related Myopathies
3.2 RyR1 Channelopathies
3.2.1 Central Core Disease (CCD) and Dusty Core Disease (DuCD)
3.2.2 Other Congenital Myopathies Caused by RyR1 Mutations
3.3 STAC3 Channelopathies
3.3.1 Native American Myopathy (NAM)
3.4 Channelopathies Caused by Several EC Coupling Proteins
3.4.1 Malignant Hyperthermia (MH) Susceptibility
Intro
Preface
1. A Bumpy Road Toward Drug Therapies in Ca2+ Channelopathies
2. Toward Advanced Technology Medicinal Products Targeting Ca2+-Channels
3. Ca2+-Channel Modulation: New Discoveries Answer (Very) Old Questions
Contents
Part I: Modulation
CaV1.1 Calcium Channel Signaling Complexes in Excitation-Contraction Coupling: Insights from Channelopathies
1 Skeletal Muscle Excitation-Contraction (EC) Coupling
2 Essential Proteins for Skeletal Muscle Excitation-Contraction Coupling
2.1 The Voltage-Sensor CaV1.1
2.2 The Calcium Release Channel RyR1
3.4.2 Myotonic Dystrophy Type 1 (DM1)
4 Summary and Perspective
References
Mechanisms of Vascular CaV1.2 Channel Regulation During Diabetic Hyperglycemia
1 Introduction
2 Role of CaV1.2 in Smooth Muscle Cells
3 Effects of Diabetic Hyperglycemia on Vascular CaV1.2
4 Mechanisms
5 Pathophysiological Impact
6 Conclusions/Future Directions
References
Sympathetic Nervous System Regulation of Cardiac Calcium Channels
1 Introduction
2 Biophysical Signature of Adrenergic Regulation of L-Type Channels
3 Molecular Mechanisms Underlying L-Type Upregulation
1 Cardiovascular CaV1.2 Channel at a Glance
2 Galectin-1
2.1 Galectin-1 Overview
2.2 Galectin-1-Mediated CaV1.2 Regulation in Hypertension
2.3 Galectin-1 in Cardiac Diseases
2.4 Regulatory Signalling of Galectin-1
2.5 Other Galectins
2.5.1 Galectin Localization and Functions
2.5.2 Galectin-3 in Cardiovascular Diseases
3 Cereblon
4 CaV1.2, Sialylation, and COVID-19
5 Concluding Remarks
References
Part II: Pharmacological Approaches
The Role of Striatal Cav1.3 Calcium Channels in Therapeutics for Parkinsonś Disease